scientifyRESEARCH
research funding database

RESEARCH FUNDING

Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allowed) (worldwide)

Share this post

Logo of scientifyRESEARCH and Enago "Author First, Quality First" scientifyRESEARCH recommends English editing and author support services from Enago.

The Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allowed) funding program from the National Institutes of Health supports optimization and characterization of technologies and assays with the potential for utilization and adoption in regulatory submissions of genome editing therapeutics. The purpose of this 3-year U01 NOFO is to support the optimization and evaluation of IND-enabling technologies and assays to help accelerate the clinical development and evaluation of novel somatic cell genome editing therapeutics to treat a broad array of rare and common diseases.

Applications are open to researchers at research institutions in the USA and worldwide. Applications are also open to small businesses. There are no limits for the amount of funding but they must reflect the actual cost of the proposed project.  The maximum project period is 3 years.

Opportunity number: RFA-RM-24-007.

Letters of intent are due on June 26, 2024 and full applications are due on July 26, 2024.

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

Sign-up for our monthly
research funding newsletter

you can unsubscribe at any time

Be the first to know

Sign-up for Personalized Grant Alerts

Logo3